GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (FRA:RI2) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Rigel Pharmaceuticals (FRA:RI2) Future 3-5Y EPS without NRI Growth Rate : 15.77 (As of May. 16, 2025)


View and export this data going back to . Start your Free Trial

What is Rigel Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate is 15.77.

Competitive Comparison of Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate falls into.


;
;

Rigel Pharmaceuticals  (FRA:RI2) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Rigel Pharmaceuticals Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (FRA:RI2) » Definitions » Future 3-5Y EPS without NRI Growth Rate
Comparable Companies
BNTC ARCT HRTX ALLO OLMA AUTL TRDA CKPT MAZE TSHA VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
RIGL:USA
Address
611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080
Website
https://www.rigel.com
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals Headlines

No Headlines